Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

NCT04891770 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04891770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04891770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2021
Completion date
July 19, 2024
Enrollment
103 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b